Overview

This trial is active, not recruiting.

Conditions major depressive disorder, bipolar disorder, serum biomarkers
Treatment mddscoretm
Sponsor University of Utah
Start date July 2013
End date July 2015
Trial size 75 participants
Trial identifier NCT01957501, Ridge II

Summary

Depression and bipolar disorder are major public health concerns for adolescents today. Teenage depression and bipolar disorder are associated with social isolation, family stress, school failure, substance abuse and suicide. Screening for depression and bipolar disorder so that treatment can be started early in the course of illness is an urgent public health priority. Many teens with bipolar disorder are incorrectly diagnosed as having unipolar depression. It is critical that adolescents receive proper screening and assessment that leads to an accurate diagnosis and treatment. An efficient, cost-effective, blood-based screening program could be performed on an annual or semi-annual basis to potentially detect depression and then differentiate between unipolar and bipolar depression. If this type of screening were able to detect a significant percentage of teens with depression or bipolar disorder, the positive impact on U.S. public health would be substantial. The purpose of this study is to conduct a pilot study to assess the probability of detecting adolescent unipolar and bipolar depression through blood samples.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional
Arm
mddscoretm
The child will receive a single blood draw (about 10 mL).
mddscoretm
The child will receive a single blood draw (about 10 mL).
mddscoretm
The child will receive a single blood draw (about 10 mL).

Primary Outcomes

Measure
Biomarker for Major Depressive Disorder (MDD) and Bipolar Disorder in Adolescents
time frame: 4 years

Eligibility Criteria

Male or female participants from 13 years up to 21 years old.

Inclusion of Major Depressive Disorder Participants: 1. Male and female patients between the ages of 13 and 17 years 2. Participants must be able to give informed assent, and parent(s)/guardian(s) must be able to give informed permission for study participation 3. Diagnosis of MDD or depression not otherwise specified, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-TR criteria (DSM-IV-TR) 4. Current mood state depressed for > 2 weeks Inclusion of Bipolar Disorder Participants: 1. Male and female patients between the ages of 13 and 17 years 2. Participants must be able to give informed assent, and parent (s)/guardian (s) must be able to give informed permission for study participation 3. Diagnosis of Bipolar I Disorder, Bipolar II Disorder, or not otherwise specified, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-TR criteria 4. Current mood state depressed for > 2 weeks Inclusion of Healthy Control Participants: 1. Males and females between the ages of 13 and 17 years 2. Participants must not meet DSM-IV-TR diagnostic criteria for a psychiatric or substance abuse disorder 3. Participants must be able to give informed assent and parent (s)/guardian (s) must be able to give informed permission for study participation Exclusion Criteria: Exclusion of Major Depressive Disorder and Bipolar Disorder Participants: 1. Meet the DSM-IV criteria for substance abuse or dependence in the last month 2. History of fainting or other significant adverse event during blood draws in the past 3. Dysthymia 4. Daily use of oral or inhaled steroids 5. High risk of suicidal behaviors, homicidal behaviors, or self-harm 6. A medical condition, such as Addison's Disease, which is highly likely to influence the inflammatory or HPA responses Exclusion of Healthy Control Participants: 1. Clinically significant psychiatric or substance abuse disorder 2. Unstable medical or neurological illness 3. History of fainting or other significant adverse event during blood draws in the past 4. Daily use of oral or inhaled steroids 5. A medical condition, such as Addison's Disease, which is highly likely to influence the inflammatory or HPA responses

Additional Information

Official title Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel
Principal investigator Douglas Kondo, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by University of Utah.